Total Payments
$14,628
2023 Payments
$18.44
Companies
23
Transactions
132
Payment Breakdown by Category
Research$6,505 (44.5%)
Travel$5,089 (34.8%)
Food & Beverage$2,096 (14.3%)
Consulting$937.50 (6.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6,505 | 56 | 44.5% |
| Travel and Lodging | $5,089 | 12 | 34.8% |
| Food and Beverage | $2,096 | 63 | 14.3% |
| Consulting Fee | $937.50 | 1 | 6.4% |
Payments by Type
General
$8,122
76 transactions
Research
$6,505
56 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,228 | 21 | $0 (2019) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $2,979 | 18 | $0 (2020) |
| ACADIA Pharmaceuticals Inc | $2,306 | 30 | $0 (2018) |
| Janssen Research & Development, LLC | $1,644 | 8 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $1,635 | 12 | $0 (2017) |
| Corcept Therapeutics | $1,221 | 8 | $0 (2019) |
| Eli Lilly and Company | $937.50 | 1 | $0 (2021) |
| SK Life Science, Inc. | $120.66 | 7 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $71.72 | 1 | $0 (2017) |
| AbbVie Inc. | $70.30 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $18.44 | 1 | AbbVie Inc. ($18.44) |
| 2022 | $196.45 | 11 | ABBVIE INC. ($32.44) |
| 2021 | $1,296 | 21 | Eli Lilly and Company ($937.50) |
| 2020 | $1,559 | 9 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($1,559) |
| 2019 | $4,538 | 29 | Boehringer Ingelheim Pharmaceuticals, Inc. ($1,898) |
| 2018 | $3,669 | 40 | ACADIA Pharmaceuticals Inc ($2,306) |
| 2017 | $3,351 | 21 | Janssen Research & Development, LLC ($1,644) |
All Payment Transactions
132 individual payment records from CMS Open Payments — Page 3 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/12/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $115.00 | General |
| 05/12/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 05/04/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | ABILIFY MYCITE (Drug) | — | In-kind items and services | $202.56 | Research |
| Study: A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE • Category: PSYCHIATRY | ||||||
| 05/04/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | ABILIFY MYCITE (Drug) | — | In-kind items and services | $122.97 | Research |
| Study: A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE • Category: PSYCHIATRY | ||||||
| 05/04/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | ABILIFY MYCITE (Drug) | — | Cash or cash equivalent | $55.20 | Research |
| Study: A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE • Category: PSYCHIATRY | ||||||
| 05/04/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | ABILIFY MYCITE (Drug) | — | In-kind items and services | $50.00 | Research |
| Study: A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE • Category: PSYCHIATRY | ||||||
| 05/04/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | ABILIFY MYCITE (Drug) | — | In-kind items and services | $50.00 | Research |
| Study: A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE • Category: PSYCHIATRY | ||||||
| 05/04/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | ABILIFY MYCITE (Drug) | — | Cash or cash equivalent | $44.82 | Research |
| Study: A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE • Category: PSYCHIATRY | ||||||
| 05/03/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | ABILIFY MYCITE (Drug) | — | In-kind items and services | $651.61 | Research |
| Study: A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE • Category: PSYCHIATRY | ||||||
| 05/03/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | ABILIFY MYCITE (Drug) | — | In-kind items and services | $122.97 | Research |
| Study: A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE • Category: PSYCHIATRY | ||||||
| 05/03/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | ABILIFY MYCITE (Drug) | — | In-kind items and services | $120.00 | Research |
| Study: A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE • Category: PSYCHIATRY | ||||||
| 03/06/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $845.26 | General |
| 03/06/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $559.44 | General |
| 03/06/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $44.99 | General |
| 03/06/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $44.99 | General |
| 03/06/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $43.21 | General |
| 03/06/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $43.21 | General |
| 03/06/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $43.21 | General |
| 03/06/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $43.21 | General |
| 03/06/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $40.00 | General |
| 03/06/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $40.00 | General |
| 05/30/2018 | Allergan Inc. | — | Food and Beverage | In-kind items and services | $32.27 | General |
| 04/13/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | In-kind items and services | $131.16 | Research |
| Study: ACP-103-034 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 04/13/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | In-kind items and services | $131.16 | Research |
| Study: ACP-103-034 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 04/13/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | In-kind items and services | $129.00 | Research |
| Study: ACP-103-034 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACP-103-034 | ACADIA Pharmaceuticals Inc | $2,306 | 30 |
| BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,559 | 9 |
| A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,420 | 9 |
| Study 876 | Corcept Therapeutics | $1,221 | 8 |
About Dr. Gerald Cephas, MD
Dr. Gerald Cephas, MD is a Public Health & General Preventive Medicine healthcare provider based in Dayton, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/14/2017. The National Provider Identifier (NPI) number assigned to this provider is 1801312673.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gerald Cephas, MD has received a total of $14,628 in payments from pharmaceutical and medical device companies, with $18.44 received in 2023. These payments were reported across 132 transactions from 23 companies. The most common payment nature is "" ($6,505).
Ad
Practice Information
- Specialty Public Health & General Preventive Medicine
- Other Specialties Public Health & General Preventive Medicine, Surgery
- Location Dayton, OH
- Active Since 08/14/2017
- Last Updated 10/05/2021
- Taxonomy Code 2083P0901X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1801312673
Products in Payments
- NUPLAZID (Drug) $2,306
- INVEGA TRINZA (Drug) $1,716
- MK-8189 (Drug) $1,635
- REXULTI (Drug) $1,559
- ABILIFY MYCITE (Drug) $1,420
- DUOPA (Drug) $70.30
- Korlym (Drug) $47.16
- PANZYGA (Biological) $45.97
- KESIMPTA (Drug) $42.31
- KYNMOBI (Drug) $38.74
- INBRIJA (Drug) $34.36
- INGREZZA (Drug) $31.51
- AMYVID (Drug) $31.38
- Fycompa (Drug) $30.00
- RYTARY (Drug) $30.00
- AUBAGIO (Drug) $29.54
- Briviact (Drug) $20.42
- NURTEC ODT (Drug) $19.80
- EMGALITY (Drug) $17.59
- NORTHERA (Drug) $11.15
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.